Key findings
- Multiply Labs and AstraZeneca will evaluate robotic automation for commercial-scale cell therapy manufacturing.
- Multiply Labs’ latest system uses four robotic arms in parallel to increase throughput with minimal process changes.
Multiply Labs has signed an agreement with AstraZeneca to evaluate whether GMP-ready (manufacturing designed to meet Good Manufacturing Practice requirements) robotic systems can be applied to commercial-scale cell therapy manufacturing.
What does Multiply Labs do?
Multiply Labs has developed an end-to-end robotic biomanufacturing system that automates industry-standard instruments used in cell therapy manufacturing.
Their systems help high-throughput manufacturing while maintaining quality and regulatory standards for clinical and commercial use.
Their CEO demonstrated their system on NVIDIA’s YouTube channel. It’s interesting to see how cell therapies are quickly jumping into Industry 4.0:
“Cell therapies are among the most promising, yet complex medicines being developed today,” says Fred Parietti, PhD, CEO of Multiply Labs. “Our mission is to make these therapies more widely available by increasing manufacturing efficiency and scale. This agreement with AstraZeneca allows us to evaluate our multi-arm robotic clusters in a setting where we can combine some of the world’s best scientific and clinical expertise with our robotic platform to build the next generation of high-throughput, GMP-ready cell therapy manufacturing.”
Multiply Labs’ newest system uses four robotic arms operating in parallel to run a range of cell therapy manufacturing instruments already used across the industry. The company says this setup is intended to reduce the need for process modification while increasing output in existing manufacturing facilities.
Company snapshot
Multiply Labs is a robotics company that builds cloud-controlled robotic systems intended to automate manufacturing for advanced therapies. The company is based in San Francisco. More information: multiplylabs.com and their LinkedIn.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
